Published in Cell on September 03, 2015
PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations. Sci Transl Med (2016) 2.16
A fate worse than death: apoptosis as an oncogenic process. Nat Rev Cancer (2016) 1.01
The multifaceted roles of fatty acid synthesis in cancer. Nat Rev Cancer (2016) 0.95
Transforming Cancer Prevention through Precision Medicine and Immune-oncology. Cancer Prev Res (Phila) (2016) 0.93
The role of myeloid cells in cancer therapies. Nat Rev Cancer (2016) 0.92
Inflammatory networks underlying colorectal cancer. Nat Immunol (2016) 0.88
Molecular pathological epidemiology: new developing frontiers of big data science to study etiologies and pathogenesis. J Gastroenterol (2016) 0.86
MLL1 is essential for the senescence-associated secretory phenotype. Genes Dev (2016) 0.85
Trial Watch-Small molecules targeting the immunological tumor microenvironment for cancer therapy. Oncoimmunology (2016) 0.84
Tumor-Induced IL-6 Reprograms Host Metabolism to Suppress Anti-tumor Immunity. Cell Metab (2016) 0.82
Regular Aspirin Use Associates With Lower Risk of Colorectal Cancers With Low Numbers of Tumor-Infiltrating Lymphocytes. Gastroenterology (2016) 0.81
Differential expression of cyclooxygenase-2 in metastatic melanoma affects progression free survival. Oncotarget (2016) 0.80
COX-2 modulates mammary tumor progression in response to collagen density. Breast Cancer Res (2016) 0.80
Synergistic COX2 Induction by IFNγ and TNFα Self-Limits Type-1 Immunity in the Human Tumor Microenvironment. Cancer Immunol Res (2016) 0.78
Mutational analysis of anal cancers demonstrates frequent PIK3CA mutations associated with poor outcome after salvage abdominoperineal resection. Br J Cancer (2016) 0.78
Mycobacteria-responsive sonic hedgehog signaling mediates programmed death-ligand 1- and prostaglandin E2-induced regulatory T cell expansion. Sci Rep (2016) 0.78
Molecular and epigenetic features of melanomas and tumor immune microenvironment linked to durable remission to ipilimumab-based immunotherapy in metastatic patients. J Transl Med (2016) 0.78
Resolution of Cancer-Promoting Inflammation: A New Approach for Anticancer Therapy. Front Immunol (2017) 0.78
Enhancing adoptive cancer immunotherapy with Vγ2Vδ2 T cells through pulse zoledronate stimulation. J Immunother Cancer (2017) 0.77
Metabolic Hallmarks of Tumor and Immune Cells in the Tumor Microenvironment. Front Immunol (2017) 0.77
PGE2 induced in and released by dying cells functions as an inhibitory DAMP. Proc Natl Acad Sci U S A (2016) 0.77
Immunotherapy: Evading immune escape: synergy of COX and immune-checkpoint inhibitors. Nat Rev Clin Oncol (2015) 0.77
COX2/mPGES1/PGE2 pathway regulates PD-L1 expression in tumor-associated macrophages and myeloid-derived suppressor cells. Proc Natl Acad Sci U S A (2017) 0.77
Killers creating new life: caspases drive apoptosis-induced proliferation in tissue repair and disease. Cell Death Differ (2017) 0.77
Hijacking GPCRs by viral pathogens and tumor. Biochem Pharmacol (2016) 0.76
MicroRNA MIR21 (miR-21) and PTGS2 Expression in Colorectal Cancer and Patient Survival. Clin Cancer Res (2016) 0.76
The Role of Prostaglandin E2 in Tumor-Associated Immunosuppression. Trends Mol Med (2015) 0.76
Leukemia-associated activating mutation of Flt3 expands dendritic cells and alters T cell responses. J Exp Med (2016) 0.76
COX-2 expression positively correlates with PD-L1 expression in human melanoma cells. J Transl Med (2017) 0.75
Cyclooxygenase in Cancer Prevention and Treatments for Actinic Keratosis. Dermatol Ther (Heidelb) (2017) 0.75
Impact of cyclooxygenase-2 and prostaglandin-E2 expression on clinical outcome after pulmonary metastasectomy. J Thorac Dis (2017) 0.75
Targeting cancer-related inflammation in the era of immunotherapy. Immunol Cell Biol (2017) 0.75
Reducing prostaglandin E2 production to raise cancer immunogenicity. Oncoimmunology (2016) 0.75
Sulindac, a non-steroidal anti-inflammatory drug, mediates breast cancer inhibition as an immune modulator. Sci Rep (2016) 0.75
Mammary Gland Involution Provides a Unique Model to Study the TGF-β Cancer Paradox. J Clin Med (2017) 0.75
A short-term increase of the postoperative naturally circulating dendritic cells subsets in flurbiprofen-treated patients with esophageal carcinoma undergoing thoracic surgery. Oncotarget (2016) 0.75
A gene expression inflammatory signature specifically predicts multiple myeloma evolution and patients survival. Blood Cancer J (2016) 0.75
A Nonselective Cyclooxygenase Inhibitor Enhances the Activity of Vinblastine in a Naturally-Occurring Canine Model of Invasive Urothelial Carcinoma. Bladder Cancer (2016) 0.75
Regulation of myeloid cells by activated T cells determines the efficacy of PD-1 blockade. Oncoimmunology (2016) 0.75
Cyclooxygenase-2 in glioblastoma multiforme. Drug Discov Today (2016) 0.75
Oncolytic Virus-Mediated Targeting of PGE2 in the Tumor Alters the Immune Status and Sensitizes Established and Resistant Tumors to Immunotherapy. Cancer Cell (2016) 0.75
Establishment and characterization of an orthotopic patient-derived Group 3 medulloblastoma model for preclinical drug evaluation. Sci Rep (2017) 0.75
Cancer Prevention: Lessons Learned and Future Directions. Trends Cancer (2016) 0.75
Accurate quantification of PGE2 in the polyposis in rat colon (Pirc) model by surrogate analyte-based UPLC-MS/MS. J Pharm Biomed Anal (2017) 0.75
The MEK inhibitor selumetinib complements CTLA-4 blockade by reprogramming the tumor immune microenvironment. J Immunother Cancer (2017) 0.75
Aspirin Use and Colorectal Cancer Survival According to Tumor CD274 (Programmed Cell Death 1 Ligand 1) Expression Status. J Clin Oncol (2017) 0.75
The role of dendritic cells in cancer. Semin Immunopathol (2016) 0.75
Agonist immunotherapy restores T cell function following MEK inhibition improving efficacy in breast cancer. Nat Commun (2017) 0.75
The interplay between metabolic remodeling and immune regulation in glioblastoma. Neuro Oncol (2017) 0.75
Role of Type I and II Interferons in Colorectal Cancer and Melanoma. Front Immunol (2017) 0.75
Exploring the TRAILs less travelled: TRAIL in cancer biology and therapy. Nat Rev Cancer (2017) 0.75
A Unique Cellular and Molecular Microenvironment Is Present in Tertiary Lymphoid Organs of Patients with Spontaneous Prostate Cancer Regression. Front Immunol (2017) 0.75
Role of Aspirin in Breast Cancer Survival. Curr Oncol Rep (2017) 0.75
Platelets subvert T cell immunity against cancer via GARP-TGFβ axis. Sci Immunol (2017) 0.75
EGFR signaling promotes inflammation and cancer stem-like activity in inflammatory breast cancer. Oncotarget (2017) 0.75
Adaptor Protein p62 Promotes Skin Tumor Growth and Metastasis and is Induced by UVA Radiation. J Biol Chem (2017) 0.75
Intratumoral infection by CMV may change the tumor environment by directly interacting with tumor-associated macrophages to promote cancer immunity. Hum Vaccin Immunother (2017) 0.75
Hallmarks of cancer: the next generation. Cell (2011) 140.01
Cancer-related inflammation. Nature (2008) 34.21
Immunity, inflammation, and cancer. Cell (2010) 28.27
Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science (2011) 15.79
Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials. Lancet (2010) 11.00
The immune contexture in human tumours: impact on clinical outcome. Nat Rev Cancer (2012) 10.90
Smoldering and polarized inflammation in the initiation and promotion of malignant disease. Cancer Cell (2005) 9.06
Batf3 deficiency reveals a critical role for CD8alpha+ dendritic cells in cytotoxic T cell immunity. Science (2008) 7.87
Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting. Nature (2012) 7.76
Natural innate and adaptive immunity to cancer. Annu Rev Immunol (2011) 7.09
Eicosanoids and cancer. Nat Rev Cancer (2010) 5.96
The future of immune checkpoint therapy. Science (2015) 5.59
Innate and adaptive immune cells in the tumor microenvironment. Nat Immunol (2013) 5.43
Oncogenic Braf induces melanocyte senescence and melanoma in mice. Cancer Cell (2009) 4.76
Prostaglandins and inflammation. Arterioscler Thromb Vasc Biol (2011) 4.67
Toll-like receptors and cancer. Nat Rev Cancer (2008) 4.29
BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma. Clin Cancer Res (2013) 4.28
Molecular and genetic properties of tumors associated with local immune cytolytic activity. Cell (2015) 4.16
A critical function for type I interferons in cancer immunoediting. Nat Immunol (2005) 4.14
Host type I IFN signals are required for antitumor CD8+ T cell responses through CD8{alpha}+ dendritic cells. J Exp Med (2011) 4.02
Gene signature in melanoma associated with clinical activity: a potential clue to unlock cancer immunotherapy. Cancer J (2010) 3.99
Regulation of immune responses by prostaglandin E2. J Immunol (2012) 3.93
Neutralizing tumor-promoting chronic inflammation: a magic bullet? Science (2013) 3.91
Expression of tumour-specific antigens underlies cancer immunoediting. Nature (2012) 3.89
GM-CSF Mouse Bone Marrow Cultures Comprise a Heterogeneous Population of CD11c(+)MHCII(+) Macrophages and Dendritic Cells. Immunity (2015) 3.87
Type I interferon is selectively required by dendritic cells for immune rejection of tumors. J Exp Med (2011) 3.85
Sporadic immunogenic tumours avoid destruction by inducing T-cell tolerance. Nature (2005) 3.70
Host-directed therapy of tuberculosis based on interleukin-1 and type I interferon crosstalk. Nature (2014) 3.60
Dissecting the tumor myeloid compartment reveals rare activating antigen-presenting cells critical for T cell immunity. Cancer Cell (2014) 3.40
Novel genes associated with malignant melanoma but not benign melanocytic lesions. Clin Cancer Res (2005) 3.30
Genome-wide detection of DNA double-stranded breaks induced by engineered nucleases. Nat Biotechnol (2014) 2.99
Targeting cyclooxygenase-2 in human neoplasia: rationale and promise. Cancer Cell (2003) 2.71
Host immunity contributes to the anti-melanoma activity of BRAF inhibitors. J Clin Invest (2013) 2.30
Immune modulation in cancer with antibodies. Annu Rev Med (2013) 2.23
Aspirin is associated with lower melanoma risk among postmenopausal Caucasian women: the Women's Health Initiative. Cancer (2013) 2.14
Macrophage IL-10 blocks CD8+ T cell-dependent responses to chemotherapy by suppressing IL-12 expression in intratumoral dendritic cells. Cancer Cell (2014) 2.00
T cell exclusion, immune privilege, and the tumor microenvironment. Science (2015) 1.88
Immune cell-poor melanomas benefit from PD-1 blockade after targeted type I IFN activation. Cancer Discov (2014) 1.80
Targeted prostaglandin E2 inhibition enhances antiviral immunity through induction of type I interferon and apoptosis in macrophages. Immunity (2014) 1.74
Meta-analysis on the relationship between nonsteroidal anti-inflammatory drug use and gastric cancer. Eur J Cancer Prev (2010) 1.72
Primary melanoma of the CNS in children is driven by congenital expression of oncogenic NRAS in melanocytes. Cancer Discov (2013) 1.71
Nonsteroidal anti-inflammatory drugs and breast cancer risk in the National Institutes of Health-AARP Diet and Health Study. Breast Cancer Res (2008) 1.52
Expression of cyclooxygenase 2 in human malignant melanoma. Cancer Res (2001) 1.35
Oncogenic RAS pathway activation promotes resistance to anti-VEGF therapy through G-CSF-induced neutrophil recruitment. Proc Natl Acad Sci U S A (2013) 1.25
Immunomic, genomic and transcriptomic characterization of CT26 colorectal carcinoma. BMC Genomics (2014) 1.22
COX-2 inhibition potentiates antiangiogenic cancer therapy and prevents metastasis in preclinical models. Sci Transl Med (2014) 1.19
Type I interferon-associated recruitment of cytotoxic lymphocytes: a common mechanism in regressive melanocytic lesions. Am J Clin Pathol (2005) 1.18
COX-2 expression in malignant melanoma: a novel prognostic marker? Melanoma Res (2009) 1.14
Expression of cyclooxygenase-2 in benign naevi and during human cutaneous melanoma progression. Melanoma Res (2006) 1.04
Analysis of cyclooxygenase 2 (COX-2) expression during malignant melanoma progression. Cancer Biol Ther (2003) 1.00
Prostaglandin E2 and programmed cell death 1 signaling coordinately impair CTL function and survival during chronic viral infection. Nat Med (2015) 0.91
GM-CSF Mouse Bone Marrow Cultures Comprise a Heterogeneous Population of CD11c(+)MHCII(+) Macrophages and Dendritic Cells. Immunity (2015) 3.87
Diverse matrix metalloproteinase functions regulate cancer amoeboid migration. Nat Commun (2014) 1.08
Mixed lineage kinases activate MEK independently of RAF to mediate resistance to RAF inhibitors. Nat Commun (2014) 0.90
Alive but Confused: Heterogeneity of CD11c(+) MHC Class II(+) Cells in GM-CSF Mouse Bone Marrow Cultures. Immunity (2016) 0.75
MAPK pathway control of stem cell proliferation and differentiation in the embryonic pituitary provides insights into the pathogenesis of papillary craniopharyngioma. Development (2017) 0.75